MEDICINES OF MONOCLONAL ANTIBODIES IN ONCOLOGY
- 作者: Avdeeva Z.1, Soldatov A.1, Kiselevskiy M.2, Bondarev V.1
-
隶属关系:
- Scientific Centre for Expert Evaluation of Medicinal Products
- Russian Cancer Research Center named after N. N. Blokhin» of the of the Ministry of Health of the Russian Federation
- 期: 卷 22, 编号 2-1 (2019)
- 页面: 133-135
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119351
- DOI: https://doi.org/10.31857/S102872210006426-3
- ID: 119351
如何引用文章
全文:
详细
The medicines of monoclonal antibody which are successfully applied in clinical practice to treatment of oncological diseases are result of scientific achievements of biotechnology developments and researches in the field of molecular immunology. However, despite efficiency of use of the specified biotherapeutic drugs, remains many unresolved questions evolving when developing new medicines from recombinant proteins and at their clinical use. It is connected with the choice of a target antigen taking into account carcinogenesis mechanisms when developing medicine, comprehensive assessment of qualitative characteristics of recombinant protein, providing appropriate conditions of production, assessment of safety of a clinical use connected, first of all, with manifestations of «undesirable» immunogenicity of medicine.
作者简介
Zh. Avdeeva
Scientific Centre for Expert Evaluation of Medicinal Products
编辑信件的主要联系方式.
Email: avd-cytok@yandex.ru
PhD, professor, Chief Expert of Office of expertise allergens, cytokines and other immunomodulators,
Moscow
俄罗斯联邦A. Soldatov
Scientific Centre for Expert Evaluation of Medicinal Products
Email: fake@neicon.ru
PhD, Chief Expert of Office of expertise allergens, cytokines and other immunomodulators,
Moscow
俄罗斯联邦M. Kiselevskiy
Russian Cancer Research Center named after N. N. Blokhin» of the of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, professor, Head of the laboratory of cellular immunity,
Moscow
俄罗斯联邦V. Bondarev
Scientific Centre for Expert Evaluation of Medicinal Products
Email: fake@neicon.ru
PhD, professor, Director,
Moscow
俄罗斯联邦参考
- Teng M. W., Galon J., Fridman W. H., Smyth M. J. From mice to humans: developments in cancer immunoediting. J Clin Invest. 2015 Sep; 125(9):3338–46. doi: 10.1172/JCI80004. PMID: 26241053.
- Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378): 480–9.
- Vannemann M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev Cancer. 2012; 12: 237–50.
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002; 24: 1720–40.
- Bartelds G. M., Krieckaert C. L., Nurmohamed M. T., van Schouwenburg P. A., Lems W. F., Twisk J. W., Dij kmans B. A., Aarden L., Wolbink G. J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305: 1460–8.
